Recruiting
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
ClinicalTrials.gov IDNCT06057051
PhaseNA
Enrollment245
SponsorGlaukos Corporation
Age35 Years
SexALL
Conditions studied
Glaucoma
About this study
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
Interventions
- Device: iStent Infinite — iStent Infinite Trabecular Micro-Bypass System
Primary outcomes
- Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline (12 Months)
Eligibility information
Inclusion Criteria:
* Diagnosis of primary open-angle glaucoma
* Phakic or pseudophakic
* Age 35 years or older
Exclusion Criteria:
* Traumatic, uveitic, neovascular, angle-closure glaucoma or
* glaucoma associated with vascular disorders
* Active corneal inflammation or edema
* Retinal disorders not associated with glaucoma
Study locations
- Glaukos Investigator Site, Cincinnati, Ohio 45242 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.